142 related articles for article (PubMed ID: 38458096)
1. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021.
Lemos-Luengas EV; Rentería-Valoyes S; Muñoz DMA; Gonzalez CKG; Guerrón-Gómez G; Ramos-Castaneda JA
Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116235. PubMed ID: 38458096
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
Torres-Castillo LC; Fandiño C; Ramos MP; Ramos-Castaneda JA; Rioseco ML; Juliet C
J Glob Antimicrob Resist; 2023 Dec; 35():143-148. PubMed ID: 37714380
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
5. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
Braz J Infect Dis; 2022; 26(3):102369. PubMed ID: 35618040
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
8.
Stone G; Wise M; Utt E
Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
Rossolini GM; Stone GG
Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
[TBL] [Abstract][Full Text] [Related]
11. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Lin LY; Debabov D; Chang W; Stone G; Riccobene T
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
[No Abstract] [Full Text] [Related]
13. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
Tuan Soh TS; Salvinder S; Chen VSY
Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
15.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
16. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
[TBL] [Abstract][Full Text] [Related]
17. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China.
Zhou M; Cheng J; Liu Y; Hu Y; Liu Y; Lu J; Zhang S; Yu Y; Huang X; Yang Q; Liao K; Jin Y; Huang W; Feng X; Yang Q; Xu Y
Clin Infect Dis; 2018 Nov; 67(suppl_2):S206-S216. PubMed ID: 30423043
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
